WST — West Pharmaceutical Services, Inc.

Summary of West's Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenues: $805 million, up 5% organically, exceeding expectations.
• Adjusted Operating Margin: 21.1%, slightly down 40 basis points year-over-year but ahead of guidance.
• Adjusted EPS: $1.96, a 6% increase compared to the prior year and $0.26 above guidance.
• Gross Margin: 36.6%, up 120 basis points year-over-year, driven by a favorable product mix and operational efficiencies.
• Free Cash Flow: $294 million, a 54% increase year-over-year, attributed to a 23% reduction in capital expenditures.

2. Strategic Updates and Business Highlights:

• Proprietary Products Segment: Revenues of $648 million, up 5.1% organically, with strong growth in HVP components (up 13% organically), particularly from GLP-1 elastomers, which now account for 9% of total sales.
• Contract Manufacturing Segment: Revenues of $157 million, growing 4.9% organically, driven by self-injected devices for obesity and diabetes.
• Leadership Changes: New CFO Bob McMahon and CTO Davis Matter appointed, expected to enhance innovation and operational efficiency.
• Ongoing Projects: 375 Annex 1 upgrade projects in progress, anticipated to contribute 200 basis points of growth this year.

3. Forward Guidance and Outlook:

• Full-Year Revenue Guidance: Increased to $3.06 billion to $3.07 billion, representing reported growth of 5.8% to 6.1%.
• Adjusted EPS Guidance: Raised to $7.06 to $7.11, reflecting year-on-year growth of 4.6% to 5.3%.
• Q4 Revenue Guidance: Expected between $790 million to $800 million, with organic growth impacted by a prior year incentive fee.
• 2026 Outlook: Anticipated continuation of growth in HVP components driven by GLP-1s and Annex 1 upgrades, though some caution due to potential contract transitions.

4. Bad News, Challenges, or Points of Concern:

• HVP Delivery Device Business: Revenues declined year-over-year due to a $19 million incentive payment received last year, with ongoing evaluations for maximizing business value.
• Contract Manufacturing Transition: The exit from the CGM contract by mid-2026 poses a $40 million headwind, though management is optimistic about backfilling with higher-margin business.
• Market Dynamics: While demand is improving, there are still uncertainties regarding new drug approvals and potential headwinds from regulatory changes affecting customer investment decisions.

5. Notable Q&A Insights:

• Long-Term Growth: Management expressed confidence in achieving long-term growth targets (7%-9%) driven by HVP components, particularly in biologics and GLP-1s.
• Sustainability of GLP-1 Growth: While GLP-1 elastomer growth has been strong, management indicated that growth rates may normalize as the market matures.
• Visibility and Risk Management: The company is focused on improving visibility into market dynamics and reducing risks, with ongoing discussions with customers to ensure alignment with their needs.
• Capital Allocation: Plans to define a clearer capital allocation strategy, balancing between share repurchases and potential M&A opportunities.

This summary encapsulates the key points from West's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, guidance, and areas of concern.